5006802026-04-012026-06-305006802026-04-012026-06-30in-capmkt:OtherExpenses1Member5006802026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500680PFIZERNOTLISTEDINE182A01018Pfizer LimitedMain BoardEquity2026-04-012027-03-312026-07-282026-07-20INRCroresQuarterlyFirst quarterSingle segmentFinancial Results2026-07-2812:00:002026-07-2812:45:00Not applicablefalsefalseThe Company has not defaulted on loans or debt securties 2026-04-012026-06-30UnauditedStandalone6531700000448400000698010000010502000001828900000-478000000820800000146000001426000008342000004213300000276680000002766800000709300000128000007221000000204470000000002044700000-540000020393000004575000001044.6944.690044.6944.691. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on July 28, 2026. <br /> <br /> 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). <br /> <br /> 3. The financial results for the quarter ended June 30, 2026 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in <br /> <br /> 4.Figures for the quarter ended March 31, 2026 represent the difference between the audited figures in respect of the full financial year and published unaudited figures of nine months ended December 31, 2025 which were subject to a limited review by the statutory auditors. <br /> <br /> 5. Exceptional Items of Rs.49.16 crore for the year ended March 31, 2026 includes <br /> <br /> i.The charge of Rs. 41.73 crore for the year towards personnel separation cost of field force and marketing teams as a result of an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium and also includes personnel separation cost for other support functions. <br /> ii.Effective 21 November 2025, the Government of India had consolidated several existing labour laws into a unified framework consisting of four Labour Codes, collectively known as the ‘New Labour Codes’. The Company had carried out an assessment based on the best available information and legal opinion, which has resulted in increase in the provision for employee benefits by Rs. 7.43 crore for the year. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <br /> <br /> 6. The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosure relating to segments is not applicable and accordingly not made. <br /> <br /> 7. The Company does not have any subsidiary company or associate company or joint venture company as at June 30, 2026.Other Expenses834200000Items that will not be reclassified subsequently to profit or loss-7200000-7200000-18000000-5400000